RxDoctor Payments Data

Diana Hannoch-Bowie

Adult Health · Hamburg, NJNPI 1679560494

Payments from drug & device makers

$575in general payments, 2019–2025

Across 38 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$164
  • AbbVie$117
  • Lilly USA, LLC$61
  • Exact Sciences$49
  • AstraZeneca$48
  • Pfizer$41
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$575 in reported general payments places this provider in the 60th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$82,697
Medicare patients
199
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$67,661
JardianceEmpagliflozin47$49,983
EliquisApixaban72$49,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$27,773
RybelsusSemaglutide15$24,578
JanuviaSitagliptin Phosphate30$17,023
FarxigaDapagliflozin Propanediol12$16,735
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$16,726
Janumet XrSitagliptin Phos/Metformin Hcl12$12,177
Breo ElliptaFluticasone/Vilanterol31$11,807
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$9,723
Incruse ElliptaUmeclidinium Bromide16$7,625
Albuterol Sulfate HfaAlbuterol Sulfate77$3,734
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,317
Boostrix TdapDiphth,pertuss(Acell),tet Vac42$2,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$164$92,23954 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix$40$50,521104 claims
PfizerEliquis$41$49,51472 claims
AstraZenecaFarxiga, Breztri Aerosphere$48$33,46125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Hamburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →